Benefits from the correction of vitamin D deficiency in patients with pulmonary hypertension
Caspian J Intern Med 2016; 7(4):253-259
Ahmad Mirdamadi (MD) 1 Pouya Moshkdar (MD) 2 *
Department of Cardiology, Islamic Azad University, Najafabad Branch, Isfahan, Iran.
Islamic Azad University, Najafabad Branch, Isfahan, Iran.
* Correspondence: Pouya Moshkdar, Islamic Azad University, Najafabad Branch, Isfahan, Iran.
E-mail: pooya.moshkdar at gmail.com Tel: 0098 3134481192 Fax: 0098 3134481192
Pulmonary hypertension is hypertension of blood leading to the lungs
Pulmonary hypertension is a rare disease - < 200,000 per year in US
Pulmonary hypertension WikiPedia
See also VitaminDWiki
- Pulmonary Hypertension deaths prevented by 80 ng of Vitamin D (in rats) – July 2017
- The relationship between vitamin D deficiency and pulmonary hypertension – 2013
- Overview Hypertension and Vitamin D Magnesium and Omega-3 also reduce standard hypertension
- Incidence of 22 health problems related to vitamin D have doubled in a decade has the following
Pulmonary Hypertension increased 88% in a decade
Pulmonary hypertension (PH) is high blood pressure in the arteries to your lungs.
Download the PDF from VitaminDWiki
Background: Vitamin D (Vit D) is linked to various conditions including musculoskeletal, metabolic and cardiopulmonary diseases. However, it is not clear whether correction of vit D deficiency exerts any beneficial effect in patients with pulmonary hypertension.
Methods: This study was a prospective uncontrolled longitudinal study. Patients with pulmonary hypertension and vit D deficiency were enrolled into this study. All patients in addition to standard treatment for pulmonary hypertension received cholecalciferol at a dose of 50,000 IU weekly plus calcicare (at a dose of 200 mg magnesium + 8 mg zinc + 400 IU vit D) daily for 3 months. Serum level of 25-hydroxy vit D, serum level of probrain natriuretic peptide, six minute walk test (6MWT), peak and mean pulmonary artery pressure, right ventricular size and function, ejection fraction (EF) and New York Heart Association (NYHA) functional class were measured at baseline and after 3 months of treatment.
Results: Twenty-two patients with pulmonary hypertension and vit D deficiency were enrolled into the study. At endpoint, the serum vit D level increased significantly to 54.8 ng/ml, the mean of baseline distance of 6MWT increased significantly to 81.6 m and the RV size significantly improved. The mean pulmonary artery pressure also improved after the intervention, but their changes did not reach to statistically significant levels.
Conclusion: Vit D replacement therapy in patients with pulmonary arterial hypertension and vit D deficiency results in significant improvement of right ventricular size and 6 MWT. Moreover, mean pulmonary artery pressure improves nonsignificantly. This issue requires further studies with long-term follow-up period.